Cleveland biotechnology company Athersys Inc. (NASDAQ:ATHX) has reached an agreement with Japanese drugmaker Healios KK to broaden their collaboration into new therapeutic areas.
Under terms of the deal, Healios obtained exclusive licenses for the development and commercialization in Japan of Athersys’ MultiStem therapy for the treatment of acute respiratory distress syndrome (ARDS).
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell. Originally published June 7, 2018.